| Market Cap | 4.69B |
| Revenue (ttm) | 459.38M |
| Net Income (ttm) | 206.77M |
| Shares Out | 238.73M |
| EPS (ttm) | 0.84 |
| PE Ratio | 23.62 |
| Forward PE | 25.53 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,628,678 |
| Open | 19.26 |
| Previous Close | 19.20 |
| Day's Range | 19.23 - 19.97 |
| 52-Week Range | 6.84 - 25.67 |
| Beta | 0.57 |
| Analysts | Strong Buy |
| Price Target | 24.25 (+23.32%) |
| Earnings Date | May 7, 2025 |
About ADMA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface an... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ADMA stock is "Strong Buy." The 12-month stock price forecast is $24.25, which is an increase of 23.32% from the latest price.
News
ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss
ADMA Biologics has demonstrated significant revenue growth, margin expansion, and profitability, leading to a 1,314% increase in share price since 2021. The company's Q1 performance showed a 40% YoY r...
ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript
ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossm...
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue ( 1) of $118.6 Million), a 40% YoY Increase
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity
ADMA Biologics Statement on Tariffs
Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain Reiterates Strategic Advanta...
ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential
ADMA Biologics shows robust revenue growth, driven by its innovative IVIG product, ASCENIV, which targets primary humoral immunodeficiency and includes RSV antibodies. Q4 earnings reveal a 59% year-ov...
BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of Controls
Block & Leviton is investigating ADMA Biologics for potential securities fraud. Investors who lost money in ADMA should contact the firm to learn more.
ADMA Biologics, Inc. (ADMA) Q4 2024 Earnings Call Transcript
ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Gros...
ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA (1) of $164.6 ...
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manu...
ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add
ADMA Biologics specializes in primary immune deficiencies with Asceniv, a high-margin, unique product that outperforms competitors and has significant growth potential in the U.S. market. Asceniv's hi...
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
Cash on Hand Utilized to Repay $30 Million of Senior Secured Term Loan Facility to Ares Capital Lowers ADMA's Total Debt to $75 Million, a 29% Reduction Further Supports Earnings Growth Outlook RAMSEY...
ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologic...
ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologic...
ADMA Biologics, Inc. Is Being Investigated For Defrauding The Public And Affected Investors Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics...
ADMA Biologics, Inc. Is Being Investigated For Fraud And Investors With Losses Are Invited To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics...
ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics...
ADMA Biologics, Inc. Is Being Looked Into For Securities Fraud And Investors With Losses Are Invited To Assist The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics...
ADMA Biologics: Capitalizing On A $20 Billion IG Market With ASCENIV
ADMA Biologics is a rapidly growing player in plasma-derived therapies, with a 78% YoY revenue increase and a 1,300% YoY net income boost. The company's key product, ASCENIV, is expected to drive sign...
ADMA Biologics, Inc. Is Being Investigated For Fraud And Impacted Investors Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics...
ADMA Biologics, Inc. Is Being Investigated For Committing Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologic...
ADMA Biologics, Inc. Is Being Investigated For Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologic...
The Schall Law Firm Wants Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Securities Related Infractions
LOS ANGELES, CA / ACCESSWIRE / November 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologic...